[HTML][HTML] Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP …
N Kröger, G Sbianchi, T Sirait, C Wolschke, D Beelen… - Leukemia, 2021 - nature.com
Abstract JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the
impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell …
impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell …
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of …
N Kröger, G Sbianchi, T Sirait, C Wolschke, D Beelen… - Leukemia, 2021 - croris.hr
Sažetak JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the
impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell …
impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell …
[PDF][PDF] Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP …
N Kröger, G Sbianchi, T Sirait, C Wolschke, D Beelen… - 2021 - repository.ubn.ru.nl
JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of
pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation …
pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation …
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of …
N Kröger, G Sbianchi, T Sirait, C Wolschke, D Beelen… - Leukemia, 2021 - orbi.uliege.be
JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of
pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation …
pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation …
Impact of prior jak-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the cmwp of ebmt
N Krger, G Sbianchi, T Sirait, C Wolschke, DW Beelen… - 2021 - lilloa.univ-lille.fr
Abstract JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the
impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell …
impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell …
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of …
N Kröger, G Sbianchi, T Sirait, C Wolschke, D Beelen… - Leukemia, 2021 - cnrs.hal.science
Abstract JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the
impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell …
impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell …
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of …
N Kröger, G Sbianchi, T Sirait, C Wolschke, D Beelen… - Leukemia, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> JAK1/2 inhibitor ruxolitinib (RUX) is approved
in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after …
in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after …
[PDF][PDF] Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myeloibrosis: a study of the CMWP of …
N Kröger, G Sbianchi, T Sirait, C Wolschke, D Beelen… - Leukemia, 2021 - ppm.edu.pl
Abstract JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the
impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell …
impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell …
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of …
N Kroger, G Sbianchi, T Sirait, C Wolschke, D Beelen… - 2021 - ricerca.unityfvg.it
Abstract JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the
impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell …
impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell …
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of …
N Kröger, G Sbianchi, T Sirait, C Wolschke, D Beelen… - Leukemia, 2021 - hal.science
Abstract JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the
impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell …
impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell …